Skyclarys Decision: Time Is Running Out | Limerick News

Friedreich’s ataxia patients are racing against time as the final decision looms on whether a life-changing drug, Skyclarys, will be covered—after waiting over two years. With a staggering $280K annual price tag and a seven-stage approval process that repeats EU assessments unnecessarily, the system is painfully slow and opaque. Decisions made behind closed doors fuel distrust, while families desperately seek more time with loved ones. As rare disease treatments advance, balancing cost with compassion must become the new standard. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/018afa38b97cc81e